This evening news segment on new evidence showing some back surgeries aren’t effective does a very good job on many levels. It:
Given all this, one is tempted to give the segment a pass for its omissions, such as a failure to mention that the studies’ size and brevity prevent them from being conclusive and that the placebo may have had some effect that non-treatment in a clinical context would not. But two omissions are harder to overlook:
It’s true that both of these issues fall outside the findings of the studies. But so does the material about health care costs and evidence-based medicine. Some mention, at least brief, should have been made of the risks of surgery and the questions about non-surgical treatment. This would have provided a clearer picture of the findings’ implications.
As good as the segment was, it could have also helped viewers think about some important take-home questions:
This highlights what health care reform needs to do to address saving costs on expensive low return interventions.
The segment reports the procedure costs $2,000 to $5,000.
The reporter gets extra points for putting these costs in the context of larger concerns over health care spending on procedures that are not proven effective.
The segment makes only a very general statement about results: "there was no difference up to six months later for patients who actually had the procedure and those who had a fake or placebo treatment instead."
But this echoes the un-nuanced language of the conclusions stated in the abstracts. One says the improvements for the groups "were similar" and the other says the surgeries "had no beneficial effect."
The segment also made clear that patients in both groups saw improvement rather than no change, a useful observation about the benefits.
The segment therefore minimally earns a "satisfactory" rating despite its lack of detail.
Given the fact that the studies suggests the surgery has no benefits, the segment should have mentioned its risks.
Vertebroplasty is considered very safe. But it carries some risks: cement leakage into nearby tissues and the possibility [though data are inconclusive] of increasing the risk of fracture in other vertebrae. There are small risks of soft-tissue damage and nerve-root pain and compression.
Like all surgeries, vertebroplasty carries risks of bleeding, infection and anesthesia, which are higher for the elderly population than the general population.
The segment is based on results of two studies published in the New England Journal of Medicine. The studies are of very high quality: single-blinded, randomized, placebo-controlled, multi-center clinical trials.
While both studies are relatively small (131 and 78 patients), the conclusions are strengthened by the fact that they produced similar findings.
Ideally, the segment would have stated that the studies followed patients for no more than six months, leaving the question of benefits [or risks] over the longer term unanswered.
It’s also worth noting that the placebo was not a fake injection of the cement but a short-acting anesthetic, which may have had an effect on the condition that non-treatment would not.
On balance, the segment earns a satisfactory rating.
The story does nothing to exaggerate the prevalence or severity of the conditions that vertebroplasty is used to treat.
The producers earn extra points for using three well-selected sources:
The segment earns even more bonus points for using an anecdote involving someone who got the placebo procedure and still felt the surgery benefited her–a rare case when a personal story makes a point other than the usual, "Well, the treatment worked for me."
Major flaw here: The segment fails to look at non-surgical treatments for painful osteoporotic fractures that, by inference, should be more widely considered.
This is an important issue.
Patients who get this surgery are usually in considerable pain. Quality of life is reduced. While the studies suggest placebo treatment works as well as surgery, this is of little consolation to someone with a painful, disabling condition who needs relief.
Standard non-surgical treatment for painful osteoporotic fractures doesn’t work in some severe cases and carries its own risks.
Treatment usually includes use of pain relievers, including some narcotics, which can cause gastrointestinal problems, poor balance and the risk of addiction. Other pain meds are poorly tolerated in an older population.
Bed rest carries its own risks for older people with osteoporosis, including physical deterioration.
Physical therapy is often beneficial, but compliance can be low and hard to sustain.
Finally, without successful treatment, the condition can lead to joint problems, spine misalignment, impaired gait and balance, muscle spasms and falls.
The segment reports that about 40,000 vertebroplasties are done each year, implying wide availability.
The segment clearly illustrates that the procedure is not novel–and the fact that it is so widely done makes the findings relevant to the larger issue of health-care costs.
Several press releases were issued about this story, but this report does not appear to draw on them.
Systematic, Criteria-Driven
Puleeeeease... this 'game changer' weight loss drug causes more nausea and vomiting than a placebo. Some game, some change. My friend Gary would spank you for using the eighth word medical reporters should never, ever use. @garyschwitzer @thackerpd
https://www.healthnewsreview.org/toolkit/just-journalists-writing-tips-case-studies/7-words-and-more-you-shouldnt-use-in-medical-news/ https://twitter.com/OttawaCitizen/status/1361426796126830597
A scary @statnews Op-Ed warns that govt attempts to rein in Pharma may cut off access to "life-changing" drugs.
It takes @garyschwitzer to let us know: the author spent 10 years as Pfizer's public-policy chief. https://twitter.com/garyschwitzer/status/1360325022578053123
.@TranspariMED criticizes STAT op-ed for not disclosing pharma funding of author’s institute - similar to criticism we’ve made of STAT op-eds in the past. @transparify @ThinkTankWatch @icer_review https://www.healthnewsreview.org/2021/02/transparency-watchdog-criticizes-stats-non-disclosure-on-pro-pharma-op-ed/
Comments
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.